Skip to main content
Clinical Trials/NCT05570656
NCT05570656
Completed
Not Applicable

Modeling Spinal Mobility in Ankylosing Spondylitis (AS) : Towards New Telekinetic Biomarkers

University Hospital, Montpellier1 site in 1 country40 target enrollmentDecember 13, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ankylosing Spondylitis
Sponsor
University Hospital, Montpellier
Enrollment
40
Locations
1
Primary Endpoint
Variation in spinal angle measurement between APS patients and healthy volunteers
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that mainly affects the spine and pelvis in its axial form. It is responsible for chronic inflammatory pain and sometimes ankylosis with significant functional retention.

Clinicians need markers capable of precisely measuring the restriction of range of motion in these patients, reflections of the activity and/or sequelae of the disease.

The Inverstigators validated movement markers in the AS by a device including inertial sensors (XSENS) and computer modeling. The accuracy and repeatability of the XSENS-Awinda system compared to the reference measurement system have been demonstrated. The XSENS-Awinda device offers new real-time evaluation possibilities for quantitative gait analysis. This opens the way to new diagnostic tools, prognostics and therapeutic perspectives for the clinician.

Detailed Description

Ankylosing spondylitis (AS) is a chronic inflammatory rheumatic disease that mainly affects the spine and pelvis in its axial form. It is responsible for chronic inflammatory pain and sometimes ankylosis with significant functional retention. Today, these patients benefit from treatments by biotherapy but the functional monitoring of the therapeutic response is based on the clinical examination, questionnaires, and the measurement of CRP (C reactive Protein). Clinicians need markers capable of precisely measuring the restriction of range of motion in these patients, reflections of the activity and/or sequelae of the disease. The prevention and/or the restoration of these movement limitations, responsible for gait/attitude/balance disorders, are also among the therapeutic objectives of AS. In the AS, the synergy between the trunk and the lower limbs is altered with a restriction of the movements of the trunk in the three planes of space. The study of the kinematic variability seems to show a loss of complexity. In addition, MRI morphological examinations are insufficient to assess stiffness and functional disability related to AS. The investigators validated movement markers in the AS by a device including inertial sensors (XSENS) and computer modeling. The accuracy and repeatability of the XSENS-Awinda system compared to the reference measurement system have been demonstrated. The XSENS-Awinda device offers new real-time evaluation possibilities for quantitative gait analysis. This opens the way to new diagnostic tools, prognostics and therapeutic perspectives for the clinician.

Registry
clinicaltrials.gov
Start Date
December 13, 2022
End Date
September 14, 2023
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18-65
  • BMI between 18.5 and 30
  • Written informed consent
  • Same gender and age within +/- 3 years compared to an unmatched AS patient
  • Inclusion criteria specific to the AS group:
  • Age 18-65
  • BMI between 18.5 and 30
  • Written informed consent
  • AS meeting the ASAS (Assessment of Spondylo Arthritis International Society) criteria, i.e. with spinal pain ≥ 3 months old, with an age of diagnosis \< 45 years, with:
  • Sacroiliitis on imaging AND ≥ 1 sign of spondylarthritis. OR

Exclusion Criteria

  • Traumatic, tumoral or infectious low back pain
  • History of spinal fracture
  • History of lumbar, pelvis, hips, ankles, and/or knees surgery
  • Severe scoliosis defined by a Cobb angle \> 50°
  • Severe impairment of uncorrected visual acuity
  • Concomitant pathology responsible for ataxia
  • Lumbar arthrodesis of two or more stages
  • Pregnant or breastfeeding women
  • Patient unable to give consent: patient under guardianship or curators, mentally retarded, dementia, language barrier
  • Patient not affiliated to a social security plan

Outcomes

Primary Outcomes

Variation in spinal angle measurement between APS patients and healthy volunteers

Time Frame: 1 day

Assess the diagnostic performance of angular measurement in the sagittal plane during flexion and extension of the spine in the diagnosis of AS. spinal angle measurement (in degrees) for both APS patients and healthy volunteers will be compared using a Student's test or Wilcoxon Mann Whitney test depending on the distribution. The diagnostic performances of the different kinematic parameters will be estimated in percentage (%) with their 95% confidence interval.

Secondary Outcomes

  • Percentage of functional impact of the AS by BASMI score(1 day)
  • percentage of diagnosis concordant between the kinematic parameters of the lower limb joints and the diagnosis of AS(1 day)
  • Percentage of functional impact of the AS by BASFI score(1 day)
  • percentage of correlation between clinical and kinematic parameters(1 day)
  • Percentage of AS activity by BASDAI score(1 day)
  • Variation of kinematic parameters of movement between BASFI and sensors(1 day)
  • percentage of diagnosis concordant between the kinematic parameters of the spine and the diagnosis of AS(1 day)

Study Sites (1)

Loading locations...

Similar Trials